WAKEFIELD, Mass.--(BUSINESS WIRE)--BIOCIUS Life Sciences Inc., developers of the RapidFire® high-throughput mass spectrometry system, today announced a new contract research service that expands the in vitro ADME (Absorption, Distribution, Metabolism and Excretion) assays that can be analyzed quickly and efficiently using RapidFire technology. The extension of the existing CYP Inhibition service now includes analysis of a wide range of assays including microsomal stability, permeability and plasma protein binding. Additionally, BIOCIUS will offer custom services for the development of analysis methods for other ADME assays.
